Top

Published in:

01-04-2017 | Original Article

Clinical Roles of Interleukin-6 and STAT3 in Oral Squamous Cell Carcinoma

Authors: Kenichi Shinagawa, Souichi Yanamoto, Tomofumi Naruse, Akiko Kawakita, Kota Morishita, Yuki Sakamoto, Satoshi Rokutanda, Masahiro Umeda

Published in: Pathology & Oncology Research | Issue 2/2017

Abstract

The effect inflammation has on cancer prognosis is marked by the presence of cytokines and chemokines. Interleukin-6 (IL-6) is one a multifunctional cytokine that regulates inflammatory responses. We investigated the roles of IL-6 and STAT3 and examined the relationship between IL-6 signaling and clinicopathological factors in patients with oral squamous cell carcinoma (OSCC). We retrospectively examined 116 patients who underwent radical surgery for OSCC. IL-6 and STAT3 expression were detected by immunohistochemistry. IL-6 and STAT3 positivity were detected by IHC, at 78.4 and 80.2 %, respectively. IL-6 expression was significantly associated with pattern of invasion (P = 0.004), vascular invasion (P = 0.003), and pathological nodal status (P = 0.019). Multivariate logistic regression analysis revealed that IL-6 expression was significantly associated with vascular invasion (P = 0.044). Meanwhile, there was no significant association between STAT3 expression and clinicopathological factors and no significant relationship between IL-6 and STAT3 expression. IL-6 expression was significantly associated with 5-year disease-free survival. These results suggest that IL-6 is involved in lymphangiogenesis and recurrence in OSCC.

Fitzmaurice C, Dicker D, Pain A et al (2015) The global burden of cancer 2013. JAMA Oncol 1:505–527CrossRefPubMed

Rogers SN, Brown JS, Woolgar JA et al (2009) Survival following primary surgery for oral cancer. Oral Oncol 45:201–211CrossRefPubMed

Turcotte S, Rosenberg SA (2011) Immunotherapy for metastatic solid cancers. Adv Surg 45:341–360CrossRefPubMedPubMedCentral

Bell RB, Leidner R, Feng Z et al (2015) Developing an immunotherapy strategy for the effective treatment of oral, head and neck squamous cell carcinoma. J Oral Maxillofac Surg 73:S107–S115CrossRefPubMed

Chen HH, Chen IH, Liao CT et al (2011) Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol 36:147–153CrossRefPubMed

Huang SF, Wei FC, Liao CT et al (2012) Risk stratification in oral cavity squamous cell carcinoma by preoperative CRP and SCC antigen levels. Ann Surg Oncol 19:3856–3864CrossRefPubMed

Fang HY, Huang XY, Chien HT et al (2013) Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma. Laryngoscope 123:2690–2699CrossRefPubMed

Culig Z (2013) Interleukin-6 as a therapy target in oral squamous carcinoma. Expert Opin Ther Targets 17:53–59CrossRefPubMed

Jinno T, Kawano S, Maruse Y et al (2015) Increased expression of interleukin-6 predicts poor response to chemoradiotherapy and unfavorable prognosis in oral squamous cell carcinoma. Oncol Rep 33:2161–2168PubMedPubMedCentral

10.

Sato J, Ohuchi M, Wada M et al (2015) Differences in sequential posttreatment salivary IL-6 levels between patients with and patients without locoregional recurrences of oral squamous cell carcinoma: part III of a cohort study. Oral Surg Oral Med Oral Pathol Oral Radiol 120:751–760CrossRefPubMed

11.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867CrossRefPubMedPubMedCentral

12.

Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51CrossRefPubMed

13.

Heikkilä K, Ebrahim S, Lawlor DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61:824–833CrossRefPubMedPubMedCentral

14.

Allin KH, Bojesen SE, Nordestgaard BG (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27:2217–2224CrossRefPubMed

15.

Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9:798–809CrossRefPubMedPubMedCentral

16.

Kruse AL, Luebbers HT, Gratz K et al (2010) C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol 2:21CrossRefPubMedPubMedCentral

17.

Neurath MF, Finotto S (2011) IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 22:83–89CrossRefPubMed

18.

Paramanathan A, Saxena A, Morris DL (2014) A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol 23:31–39CrossRefPubMed

19.

Perisanidis C, Kornek G, Poschl PW et al (2013) High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer. Med Oncol 30:334CrossRefPubMed

20.

de Oliveira MV, Fraga CA, Gomez RS et al (2009) Immunohistochemical expression of interleukin-4, −6, −8, and −12 in inflammatory cells in surrounding invasive front of oral squamous cell carcinoma. Head Neck 31:1439–1446CrossRefPubMed

21.

Guo Y, Xu F, Lu T et al (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38:904–910CrossRefPubMed

22.

Tawara K, Oxford JT, Jorcyk CL et al (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 3:177–189PubMedPubMedCentral

23.

Yoshimura A (2006) Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 97:439–447CrossRefPubMed

24.

Mali SB (2015) Review of STAT3 (signal transducers and activators of transcription) in head and neck cancer. Oral Oncol 51:565–569CrossRefPubMed

25.

Sobin LH, Gospodarowicz MK, Wittekind C (2009) International Union against Cancer (UICC) TNM classification of malignant tumors. 7th ed. Wiley-Blackwell, Oxford

26.

Bryne M, Koppang HS, Lilleng R et al (1992) Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 166:375–381CrossRefPubMed

27.

Shinriki S, Jono H, Ueda M et al (2011) Interleukin-6 signaling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol 225:142–150CrossRefPubMed

28.

Yadav A, Kumar B, Datta J et al (2011) IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the LAK-STAT3-SNAIL signaling pathway. Mol Cancer Res 9:1658–1667CrossRefPubMedPubMedCentral

29.

Otrock ZK, Makarem JA, Shamseddine AI (2007) Vascular endothelial growth factor family of ligants and receptors: review. Blood Cells Mol Dis 38:258–268CrossRefPubMed

30.

Omoto I, Matsumoto M, Okumura H et al (2014) Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma. Oncol Lett 7:1027–1032PubMedPubMedCentral

31.

Arinaga M, Noguchi T, Takeno S et al (2003) Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97:457–464CrossRefPubMed

32.

Wakisaka N, Hirota K, Kondo S et al (2012) Induction of lymphangiogenesis through vascular endothelial growth factor-C/vascular endothelial growth factor receptor 3 axis and its correlation with lymph node metastasis in nasopharyngeal carcinoma. Oral Oncol 48:703–708CrossRefPubMed

33.

Duffy SA, Taylor JMG, Terrell JE et al (2008) Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113:750–757CrossRefPubMed

34.

Jablonska J, Leschner S, Westphal K et al (2010) Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 120:1151–1164CrossRefPubMedPubMedCentral

35.

Li MX, Liu XM, Zhang XF et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134:2403–2413CrossRefPubMed

36.

Shen L, Zhang H, Liang L et al (2014) Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Radiat Oncol 9:295CrossRefPubMedPubMedCentral

37.

Kim IY, You SH, Kim YW (2014) Neutrophil-lymphocyte ratio predicts pathologic tumor response and survival after preoperative chemoradiation for rectal cancer. BMC Surg 14:94CrossRefPubMedPubMedCentral

Title: Clinical Roles of Interleukin-6 and STAT3 in Oral Squamous Cell Carcinoma
Authors: Kenichi Shinagawa
Souichi Yanamoto
Tomofumi Naruse
Akiko Kawakita
Kota Morishita
Yuki Sakamoto
Satoshi Rokutanda
Masahiro Umeda
Publication date: 01-04-2017
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-016-0134-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Studies on the Contribution of Cox-2 Expression in the Progression of Oral Squamous Cell Carcinoma and H-Ras Activation

Oroxylin a could be a Promising Radiosensitizer for Esophageal Squamous Cell Carcinoma by Inducing G2/M Arrest and Activating Apoptosis

Low Expression LncRNA TUBA4B is a Poor Predictor of Prognosis and Regulates Cell Proliferation in Non-Small Cell Lung Cancer

Relationships between Common and Novel Interleukin-6 Gene Polymorphisms and Risk of Cervical Cancer: a Case-Control Study

Serum Heat Shock Protein 70, as a Potential Biomarker for Small Cell Lung Cancer

Mutant KRAS Status Is Associated with Increased KRAS Copy Number Imbalance: a Potential Mechanism of Molecular Heterogeneity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer